Silexion Therapeutics (NASDAQ: SLXN) fills audit seat after director exit
Rhea-AI Filing Summary
Silexion Therapeutics Corp reported changes to its Board and audit committee. Professor Amnon Peled notified the Board of his resignation from the Board and all committees, including the audit committee, effective August 1, 2026. His resignation was for personal reasons and did not result from any disagreement regarding the company’s operations, policies, or practices.
Immediately upon his resignation becoming effective, the Board appointed existing independent director Avner Lushi to the audit committee, filling the vacancy. The Board determined that Lushi meets the independence standards of Nasdaq Listing Rule 5605(c)(2)(A) and SEC Rule 10A-3(b)(1). With his appointment, the audit committee now consists of three independent members—Dror J. Abramov (chair and audit committee financial expert), Ruth Alon, and Lushi—restoring full compliance with Nasdaq’s audit committee composition requirements without using the cure period.
Positive
- The audit committee now has three independent members, restoring compliance with Nasdaq Listing Rule 5605(c)(2)(A) without relying on the cure period in Rule 5605(c)(4)(B).
Negative
- None.
Insights
Analyzing...
8-K Event Classification
Item 8.01 — Other Events
1 item
Item 8.01
Other Events
Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Key Figures
Ordinary share par value: $0.135 per share
Warrant exercise price: $15,525,00 per share
Audit committee members: 3 independent members
+1 more
4 metrics
Ordinary share par value
$0.135 per share
Par value of Silexion Therapeutics Corp ordinary shares listed on Nasdaq
Warrant exercise price
$15,525,00 per share
Exercise price for warrants exercisable for ordinary shares trading under symbol SLXNW
Audit committee members
3 independent members
Composition of Silexion’s audit committee after appointing Avner Lushi
Nasdaq audit committee minimum
3 independent members
Minimum composition required by Nasdaq Listing Rule 5605(c)(2)(A)
Key Terms
audit committee financial expert, Nasdaq Listing Rule 5605(c)(2)(A), Rule 10A-3(b)(1), emerging growth company, +1 more
5 terms
audit committee financial expert financial
"Dror J. Abramov (Chair and audit committee financial expert)"
A person on a company’s board who has deep knowledge of accounting, financial reporting and auditing, able to understand and question the books, controls and audit work like a trained mechanic inspecting an engine. Investors care because that expertise helps spot errors, weaknesses or misleading statements early, improving the likelihood that financial reports are accurate and reducing the risk of surprises that can hurt a company’s value.
Nasdaq Listing Rule 5605(c)(2)(A) regulatory
"independence requirements under both Nasdaq Listing Rule 5605(c)(2)(A)"
Rule 10A-3(b)(1) regulatory
"under both Nasdaq Listing Rule 5605(c)(2)(A) and Rule 10A-3(b)(1)"
emerging growth company regulatory
"Emerging growth company"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
cure period regulatory
"without having relied on the cure period provided under Nasdaq Listing Rule 5605(c)(4)(B)"
A cure period is a set amount of time given to a borrower, counterparty, or contracting party to fix a missed payment, breach, or other problem before more serious consequences—like penalties, higher interest, or contract termination—kick in. For investors, it matters because it creates a short grace window that can prevent immediate losses and influence the timing and likelihood of recovery; think of it like a few extra days to pay a bill before a service is cut off.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What board change did Silexion Therapeutics (SLXN) disclose in August 2026?
Silexion Therapeutics reported that Professor Amnon Peled resigned from its Board and all committees, effective August 1, 2026, for personal reasons. The company stated his resignation did not result from any disagreement over its operations, policies, or practices.
Who replaced Professor Amnon Peled on the Silexion (SLXN) audit committee?
The Board appointed Avner Lushi, an existing independent director, to the audit committee effective August 1, 2026. His appointment immediately filled the vacancy created by Peled’s resignation and returned the audit committee to three independent members.
Does Silexion Therapeutics (SLXN) now meet Nasdaq audit committee requirements?
Yes. After appointing Avner Lushi, Silexion’s audit committee again has three independent members, satisfying Nasdaq Listing Rule 5605(c)(2)(A). The company restored full compliance without using the cure period available under Nasdaq Listing Rule 5605(c)(4)(B).
What independence standards does Silexion (SLXN) say Avner Lushi satisfies?
The Board determined that Avner Lushi meets independence requirements for audit committee members under both Nasdaq Listing Rule 5605(c)(2)(A) and SEC Rule 10A-3(b)(1). These rules govern the independence of audit committee members at Nasdaq-listed companies.
Who currently serves on Silexion Therapeutics’ (SLXN) audit committee?
Silexion’s audit committee consists of three independent members: Dror J. Abramov (chair and audit committee financial expert), Ruth Alon, and Avner Lushi. This composition aligns with Nasdaq’s requirement for at least three independent audit committee members.
How long has Avner Lushi served on Silexion Therapeutics’ (SLXN) Board?
Avner Lushi has served as a member of the Board since August 2024, when Silexion’s securities were listed on the Nasdaq Stock Market. He brings extensive board experience and leads the Guangzhou Sino-Israel Bio-industry Investment Fund (GIBF).